domatinostat/Rapamycin (VUJ-100) / 4SC, Vuja De Sciences - LARVOL DELTA

Vuja De Sciences Announces FDA Clearance of Investigational New Drug (IND) Application for VUJ-100 (PRWeb) - "Vuja De Sciences...announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for VUJ-100 for the treatment of relapsed, refractory sarcoma and osteosarcoma on Sep 11, 2024....The Phase 1/2 trial will be conducted by Sunshine/NPCF with the support of Vuja De."

IND • New P1/2 trial • Osteosarcoma